MarketMoodz
Edgewise’s EDG-7500 Improves Heart Function, Sets Stage for Phase 3
Edgewise Therapeutics released topline 12-week Part D results from its Phase 2 CIRRUS-HCM trial showing meaningful heart-function improvements with EDG-7500 in both obstructive and nonobstructive hypertrophic cardiomyopathy. The data — coupled with a $1.55 billion upfront sale of its muscular dystrophy business to Servier — strengthens the company’s balance sheet and clears room to advance a potential Phase 3 program.
Key Takeaways
- Topline Part D results cover 53 patients (20 oHCM, 33 nHCM) dosed 25–150 mg over 12 weeks.
- In oHCM, EDG-7500 produced significant reductions in LVOT gradient at rest and with Valsalva, with 90% of patients showing hemodynamic improvement.
- Nearly 75% of oHCM patients achieved NT‑proBNP normalization or ≥50% reduction; nHCM patients averaged a 65% NT‑proBNP drop with 88% meeting the normalization/≥50% threshold.
- Seventy percent of patients improved by at least one NYHA class and patient-reported outcomes improved by an average of 13 points.
- Safety called favorable: most adverse events mild/moderate, no meaningful decline in ejection fraction and no EF below 50%; two new-onset atrial fibrillation cases were reported but deemed unrelated.
People Involved
- No specific individuals mentioned
Entities Involved
- Edgewise Therapeutics Inc. (EWTX)Sponsor of EDG-7500 and developer of the Phase 2 CIRRUS-HCM program
- ServierBuyer of Edgewise's muscular dystrophy business for $1.55B upfront plus up to $1.1B in milestones
MarketMoodz Analysis
For investors, the Part D topline reads like a proof-of-concept: EDG-7500 showed hemodynamic benefit in obstructive HCM and large NT‑proBNP declines in nonobstructive patients—both meaningful surrogate markers for symptom relief and disease activity. The trial’s safety signals are equally important; no drop in left ventricular ejection fraction below 50% and mostly mild/moderate adverse events reduce the acute regulatory risk that has complicated other sarcomere modulators. Coupled with improved NYHA class in 70% of participants and a 13‑point gain in patient-reported outcomes, these data can justify updating Phase 3 dose selection and endpoints and support discussions with regulators.
Context matters: the HCM space already has an approved sarcomere modulator (mavacamten/Camzyos), which validated the mechanism but left open questions about broader dosing, monitoring and nonobstructive disease. EDG-7500’s reported NT‑proBNP drops (65% average in nHCM) and high responder rates would, if replicated in larger cohorts, position Edgewise as a competitor with a differentiated profile—especially if confirmatory data maintain the favorable ejection fraction and safety profile. That said, these are topline, press-release–level figures from a 53‑patient cohort; investors should treat them as directional until detailed datasets and peer-reviewed results are available.
What to watch next: full data disclosure with numeric LVOT-G changes, responder definitions and subgroup breakdowns; Phase 3 design choices (primary endpoint, sample size, dose), any scheduled interactions with the FDA, and timing of a pivotal filing. The Servier deal ($1.55B upfront, up to $1.1B in milestones) materially improves Edgewise’s runway and reduces near-term financing risk, but market reaction—EWTX was roughly $34.29 and down about 2.6% at publication—suggests investors will demand full datasets before re-rating the stock.
Source: Original Article